USPTO’s Lax Policy Leads to Humira Formulation Thicket
Journal of Law, Medicine & Ethics · 2024
DOI: 10.1017/jme.2024.132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Law, Medicine & Ethics, 2024. Verfasst von Bernard Chao. Beteiligte Einrichtung: UNIVERSITY OF DENVER, DENVER, COLORADO, USA. Hauptthemen laut MEDLINE: Patents as Topic, Biosimilar Pharmaceuticals. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Biosimilar drugs enter the United States market well after they enter the European market. That is likely because pharmaceutical companies have many more patents in the United States than in Europe. But why is patent coverage of biological drugs so much more extensive in United States? This case study seeks to answer this question for drug formulation patents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UNIVERSITY OF DENVER, DENVER, COLORADO, USA.
Zitieren
APA
Chao, B. (2024). USPTO’s Lax Policy Leads to Humira Formulation Thicket. Journal of Law, Medicine & Ethics. https://doi.org/10.1017/jme.2024.132
Vancouver
Chao B. USPTO’s Lax Policy Leads to Humira Formulation Thicket. Journal of Law, Medicine & Ethics. 2024. doi:10.1017/jme.2024.132
BibTeX
@article{Chao2024,
author = {Chao, Bernard},
title = {USPTO’s Lax Policy Leads to Humira Formulation Thicket},
journal = {Journal of Law, Medicine & Ethics},
year = {2024},
doi = {10.1017/jme.2024.132}
}
EUVIMED